AM Best Assigns Indicative Issue Credit Ratings to MetLife, Inc.'s New Shelf Registration
OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has assigned indicative Long-Term Issue Credit Ratings of 'a-' (Excellent) to senior unsecured issues, 'bbb+' (Good) to subordinated issues, and 'bbb' (Good) to preferred stock to the recently filed shelf registration of MetLife, Inc. (MetLife) (headquartered in New, NY) [NYSE: MET]. The outlook assigned to these Credit Ratings (ratings) is stable. Concurrently, AM Best has withdrawn the ratings on the previous shelf registrations, which expired.
MetLife's proforma financial leverage and the historical interest coverage ratios are in line with its current ratings, and its holding company liquidity is strong.
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Is AbbVie the Best Dividend Stock in Big Pharma Today?
AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry into this elite group. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is a leading pharmaceutical company with a strong product lineup that consistently delivers solid revenue and earnings. Its top growth drivers, Skyrizi and Rinvoq, have outperformed expectations, leading management to raise their combined 2027 sales forecast to over $31 billion. The company also benefits from other key products like Botox and a deep pipeline of new therapies to offset future patent expirations. With strong cash flow and a reliable portfolio, AbbVie Inc. (NYSE:ABBV) remains an attractive pick for income investors looking for long-term dividend stability. Naturally, if AbbVie encounters serious challenges, it could be pressured to reduce its dividend. One concern is its elevated payout ratio, currently at 267.66%. Typically, when a company's payout ratio remains above 70% for an extended time, it raises the risk of a dividend cut or suspension. However, AbbVie Inc. (NYSE:ABBV)'s next-generation immunology drugs are seeing strong growth, which could help offset the challenges it's facing from Humira. The rheumatoid arthritis treatment has been under pressure due to its loss of market exclusivity in the US and the increasing competition from biosimilars. ABBV currently offers a dividend yield of 3.5%, which is above S&P's average dividend yield of 1.3%. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Citi Increases PT on Oracle (ORCL), Keeps Neutral
Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
